Global Next Generation Diabetes Therapy and Drug Delivery Market to Reach US$ 33.5 Billion by 2032, Impelled by Rising Prevalence of Diabetes

July 11, 2023 | Healthcare IT

According to the latest report by IMARC Group, titled "Next Generation Diabetes Therapy and Drug Delivery Market by Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas), Demographic (Adult Population (>14 Years), Child Population (14 Years)), Indication (Type 1 diabetes, Type 2 diabetes), End User (Diagnostic/Clinics, Intensive Care Units (ICUs), Home Healthcare), and Region 2024-2032," the global next generation diabetes therapy and drug delivery market size reached US$ 9.8 Billion in 2023. Next-generation diabetes therapy and drug delivery refer to modern approaches and technologies aimed at improving the treatment of diabetes, mainly in terms of therapeutic effectiveness, patient convenience, and disease management. These advancements focus on delivering insulin or other antidiabetic medications more efficiently, enhancing glucose control, and reducing the burden on individuals living with diabetes. They aim to improve the lives of individuals with diabetes by enhancing treatment precision. These advancements strive to achieve better glucose control, reduce the burden of diabetes self-management, and ultimately improve long-term outcomes for individuals living with diabetes.

Global Next Generation Diabetes Therapy and Drug Delivery Market Trends:

The global market is primarily driven by the rising prevalence of diabetes among the masses. This can be attributed to the sedentary lifestyle led by individuals, unhealthy diets, and increasing obesity rates. Moreover, the growing demand for convenience and better quality of life is providing an impetus to the demand for next generation diabetes therapy and drug delivery systems as patients with diabetes often face challenges with traditional treatment methods, such as frequent injections, complex dosing regimens, and the need for constant monitoring. Furthermore, the increasing focus on personalized medicine is acting as another growth-inducing factor since next-generation therapies aim to incorporate personalized medicine approaches by leveraging technologies, including continuous glucose monitoring (CGM), data analytics, and algorithms to provide individualized treatment strategies and insulin dosing recommendations. The market is further driven by rapid advancements in technology that have paved the way for innovative diabetes therapies and drug delivery systems. For instance, the introduction of wearable devices and sensors to data analytics and artificial intelligence enables real-time monitoring, personalized treatment strategies, and automated insulin delivery systems, thereby supporting the market favorably. On account of the aforementioned factors, the market is anticipated to reach a value of US$ 33.5 Billion by 2032, exhibiting a CAGR of 14.23% during 2024-2032.

Market Summary:

On the basis of the product type, the market has been categorized into inhalable insulin, oral insulin, insulin patches, CGM systems and artificial pancreas. Among these, CGM systems represent the largest segment.
Based on the demographic, the market has been segmented into adult population (>14 years) and child population (14 years). Presently, adult population (>14 years) exhibits a clear dominance in the market.
On the basis of the indication, the market has been segregated into type 1 and type 2 diabetes. Currently, type 2 diabetes dominates the market.
Based on the end user, the market has been classified into diagnostic/clinics, intensive care units (ICUs) and home healthcare. Among these, diagnostic/clinics account for the largest market share.
Region wise, the market has been divided into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Europe (Germany, France, United Kingdom, Italy, Spain, Russia and others), Latin America (Brazil, Mexico and others) and the Middle East and Africa. Presently, North America holds the leading position in the market.
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market. Some of the key players include Abbott Laboratories, Dexcom Inc., Eli Lilly and Company, Enteris BioPharma Inc. (Swk Holdings Corporation), GlySens Incorporated, MannKind Corporation, Medtronic plc, Sanofi and Senseonics.

Report Scope:

Report Features	Details
Base Year of the Analysis	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Units	US$ Billion
Product Types Covered	Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas
Demographics Covered	Adult Population (>14 Years), Child Population (14 Years)
Indications Covered	Type 1 diabetes, Type 2 diabetes
End Users Covered	Diagnostic/Clinics, Intensive Care Units (ICUs), Home Healthcare
Regions Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered	Abbott Laboratories, Dexcom Inc., Eli Lilly and Company, Enteris BioPharma Inc. (Swk Holdings Corporation), GlySens Incorporated, MannKind Corporation, Medtronic plc, Sanofi, Senseonics, etc.
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Next Generation Diabetes Therapy and Drug Delivery Market to Reach US$ 33.5 Billion by 2032, Impelled by Rising Prevalence of Diabetes

Purchase options

Single User License ~~$3899~~ $2999
Five User License ~~$4899~~ $3999
Corporate User License ~~$5899~~ $4999

Inquire Before Buying

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.